AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
The FDA has accepted Ascelia Pharma's NDA for Orviglance, a manganese-based oral MRI contrast agent for liver imaging in patients with severe kidney impairment, and set a PDUFA action date of July 3, 2026.
Adagene and Incyte will collaborate on a Phase 1 study combining muzastotug with INCA33890 for MSS colorectal cancer patients, beginning in 2026. The collaboration marks the second instance where Adagene's SAFEbody technology is paired with a PD-1-based bispecific. Muzastotug has shown encouraging response rates in combination with pembrolizumab in previous trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07744139 |
Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis |
NOT_YET_RECRUITING | |
| NCT07727759 |
CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure |
RECRUITING | |
| NCT07717437 |
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection. |
RECRUITING | |
| NCT07281924 |
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis |
RECRUITING | PHASE1/PHASE2 |
| NCT07277322 |
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases |
RECRUITING | PHASE1/PHASE2 |
| NCT06899152 |
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer |
RECRUITING | NA |
| NCT06794086 |
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases |
RECRUITING | PHASE3 |
| NCT06287723 |
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM) |
RECRUITING | |
| NCT05829291 |
Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases |
RECRUITING | NA |
| NCT05677113 |
A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver |
ACTIVE_NOT_RECRUITING | PHASE2 |
